Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/47804
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yıldız, Fatih | - |
dc.contributor.author | Demirci, Umut | - |
dc.contributor.author | Küçükard, Ahmet | - |
dc.contributor.author | Büyükşimsek, Mahmut | - |
dc.contributor.author | Sakalar,Teoman | - |
dc.contributor.author | Topçu, Turkan | - |
dc.contributor.author | Aslan, Ferit | - |
dc.contributor.author | Tufan, Gülnihal | - |
dc.contributor.author | Aydın, Övgü | - |
dc.contributor.author | Turna, Hande | - |
dc.contributor.author | Babacan, Nalan | - |
dc.contributor.author | Başoğlu, Tuğba | - |
dc.contributor.author | Kurt, Bediz | - |
dc.contributor.author | Yıldız, Birol | - |
dc.contributor.author | Eren, Tülay | - |
dc.contributor.author | Demiray, Atike | - |
dc.contributor.author | Gümüşay, Özge | - |
dc.contributor.author | Arslan, Çağatay | - |
dc.contributor.author | Özdemir, Nuriye | - |
dc.contributor.author | Ürün, Yüksel | - |
dc.contributor.author | Baykara, Meltem | - |
dc.contributor.author | Turan, Nedim | - |
dc.contributor.author | Uysal, Mükremin | - |
dc.contributor.author | Bilici, Ahmet | - |
dc.contributor.author | Kavgacı, Halil | - |
dc.contributor.author | Cicin, İrfan | - |
dc.contributor.author | Kılıçkap, Saadettin | - |
dc.contributor.author | Paydaş, Semra | - |
dc.date.accessioned | 2023-01-09T21:30:08Z | - |
dc.date.available | 2023-01-09T21:30:08Z | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 0973-1482 | - |
dc.identifier.uri | https://doi.org/10.4103/jcrt.JCRT-950-19 | - |
dc.identifier.uri | https://hdl.handle.net/11499/47804 | - |
dc.description.abstract | Background: Merkel cell carcinoma (MCC) is a rare but highly aggressive neuroendocrine carcinoma of the skin. In this study, we aimed to evaluate the clinicopathologic characteristics, treatment outcomes, and survival of MCC cases in Turkey. Materials and Methods: The patients diagnosed with MCC between 1999 and 2018 at twenty different centers in Turkey were included in the study. Patient and tumor characteristics and adjuvant and metastatis treatment outcomes were analyzed retrospectively. Results: The median age of totally 89 patients was 70 (26-93). The most common primary location was lower limbs (n = 29, 32.5%). Immunohistochemically, CK20 positivity was present in 59 patients (66.3%). Only two patients had secondary malignancy. The majority of the patients (n = 76, 85.4%) were diagnosed at the localized stage. Surgery was performed for all patients in the early stage, and adjuvant radiotherapy or/and chemotherapy was applied to 52.6% (n = 40) of nonmetastatic patients. The median follow-up was 29 months. Recurrence developed in 21 (27.6%) of the 76 patients who presented with local or regional disease. Two-year disease-free survival (DFS) was 68.1% and 5-year DFS was 62.0% for localized stage. The 5-year DFS was similar for patients receiving adjuvant treatment (chemotherapy, radiotherapy, or sequential chemoradiotherapy) and without adjuvant therapy (P > 0.05). Two-year overall survival in patients who presented with localized disease was 71.3% and 18.5% in metastatic patients (P < 0.001). In the metastatic stage, platinum/etoposide combination was the most preferred combination regimen. Median progression-free survival (PFS) in first-line chemotherapy was 7 months (95% confidence interval: 3.5-10.5 months; standart error: 1.78). Conclusions: Although MCC is rare in Turkey, the incidence is increasing. Gender, CK20 status, tumor size, lymph node involvement, and adjuvant treatment were not associated with recurrence. © 2021 Wolters Kluwer Medknow Publications. All rights reserved. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Wolters Kluwer Medknow Publications | en_US |
dc.relation.ispartof | Journal of Cancer Research and Therapeutics | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | CK20 | en_US |
dc.subject | merkel cell carcinoma | en_US |
dc.subject | neuroendocrin carcinoma | en_US |
dc.subject | skin carcinoma | en_US |
dc.subject | avelumab | en_US |
dc.subject | carboplatin | en_US |
dc.subject | cisplatin | en_US |
dc.subject | cyclophosphamide | en_US |
dc.subject | cytokeratin 20 | en_US |
dc.subject | doxorubicin | en_US |
dc.subject | etoposide | en_US |
dc.subject | vincristine | en_US |
dc.subject | adjuvant radiotherapy | en_US |
dc.subject | adult | en_US |
dc.subject | aged | en_US |
dc.subject | Article | en_US |
dc.subject | cancer adjuvant therapy | en_US |
dc.subject | cancer combination chemotherapy | en_US |
dc.subject | cancer radiotherapy | en_US |
dc.subject | cancer recurrence | en_US |
dc.subject | cancer staging | en_US |
dc.subject | cancer survival | en_US |
dc.subject | chemoradiotherapy | en_US |
dc.subject | clinical evaluation | en_US |
dc.subject | disease free survival | en_US |
dc.subject | distant metastasis | en_US |
dc.subject | female | en_US |
dc.subject | follow up | en_US |
dc.subject | histopathology | en_US |
dc.subject | human | en_US |
dc.subject | immunohistochemistry | en_US |
dc.subject | immunosuppressive treatment | en_US |
dc.subject | limb tumor | en_US |
dc.subject | major clinical study | en_US |
dc.subject | male | en_US |
dc.subject | merkel cell carcinoma | en_US |
dc.subject | multicenter study | en_US |
dc.subject | overall survival | en_US |
dc.subject | progression free survival | en_US |
dc.subject | retrospective study | en_US |
dc.subject | treatment outcome | en_US |
dc.subject | Turkey (republic) | en_US |
dc.subject | very elderly | en_US |
dc.subject | aftercare | en_US |
dc.subject | clinical trial | en_US |
dc.subject | epidemiology | en_US |
dc.subject | incidence | en_US |
dc.subject | merkel cell carcinoma | en_US |
dc.subject | middle aged | en_US |
dc.subject | mortality | en_US |
dc.subject | prevention and control | en_US |
dc.subject | procedures | en_US |
dc.subject | skin tumor | en_US |
dc.subject | tumor recurrence | en_US |
dc.subject | turkey (bird) | en_US |
dc.subject | Adult | en_US |
dc.subject | Aftercare | en_US |
dc.subject | Aged | en_US |
dc.subject | Aged, 80 and over | en_US |
dc.subject | Carcinoma, Merkel Cell | en_US |
dc.subject | Chemoradiotherapy | en_US |
dc.subject | Disease-Free Survival | en_US |
dc.subject | Female | en_US |
dc.subject | Humans | en_US |
dc.subject | Incidence | en_US |
dc.subject | Male | en_US |
dc.subject | Middle Aged | en_US |
dc.subject | Neoplasm Recurrence, Local | en_US |
dc.subject | Neoplasm Staging | en_US |
dc.subject | Progression-Free Survival | en_US |
dc.subject | Retrospective Studies | en_US |
dc.subject | Skin Neoplasms | en_US |
dc.subject | Turkey | en_US |
dc.title | Merkel cell carcinoma in Turkey: A multicentric study | en_US |
dc.type | Article | en_US |
dc.identifier.volume | 17 | en_US |
dc.identifier.issue | 6 | en_US |
dc.identifier.startpage | 1525 | en_US |
dc.identifier.endpage | 1529 | en_US |
dc.identifier.doi | 10.4103/jcrt.JCRT-950-19 | - |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.authorscopusid | 57211777547 | - |
dc.authorscopusid | 26026850900 | - |
dc.authorscopusid | 57193238894 | - |
dc.authorscopusid | 57202022380 | - |
dc.authorscopusid | 57204201984 | - |
dc.authorscopusid | 56723995200 | - |
dc.authorscopusid | 57217031807 | - |
dc.identifier.pmid | 34916389 | en_US |
dc.identifier.scopus | 2-s2.0-85121898572 | en_US |
dc.identifier.scopusquality | Q3 | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.languageiso639-1 | en | - |
item.grantfulltext | none | - |
item.openairetype | Article | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu |
CORE Recommender
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.